Compound hub · MOTS-c
What is MOTS-c studied for? What published studies have found
MOTS-c is an experimental chain of 16 amino acids. Its code sits in the DNA of mitochondria, the energy-releasing parts of cells. The FDA states that it is not part of any FDA-approved drug. Most research uses cells and mice, starting with a 2015 paper by Lee and colleagues. Human data found so far mostly measure the body's own MOTS-c in blood. The one registered Phase 2a trial, NCT07505745, was recruiting on 14 October 2026.
01Research focusContents
Climb a steep hill and your leg muscles ask for energy faster than they did a minute ago. That energy comes from mitochondria, tiny power plants inside your cells. Mitochondria carry a small set of genes of their own, separate from the main DNA in the cell's centre. A few short messages are written in those genes. MOTS-c is one of them: a chain of 16 amino acids, the building blocks of proteins.
That unusual home is why MOTS-c has drawn so many papers since 2015. This page is part of the MOTS-c hub. It answers the questions people ask most, one study at a time. It starts with the limits of the evidence, because most of the record comes from cells and mice.
Key facts
| Common name | MOTS-c |
|---|---|
| Full name | mitochondrial open reading frame of the 12S rRNA type-c |
| Length | 16 amino acids (Lee et al., Cell Metabolism, 2015) |
| Sequence | MRWQEMGYIFYPRKLR (FDA briefing document, 11 May 2026) |
| Encoded in | Short open reading frame inside the mitochondrial 12S rRNA gene, MT-RNR1 |
| First described | 2015, Lee et al., Cell Metabolism |
| Main study models | Cultured cells and mice; the human data found are mostly blood-level measurements of the body's own peptide |
| Registered trial giving MOTS-c to people | NCT07505745, Phase 2a, recruiting; no results posted (ClinicalTrials.gov, 14 October 2026) |
| Trial of a MOTS-c analog | NCT03998514, CB4211, Phase 1a/1b, completed 19 April 2021 |
| FDA-approved drug containing MOTS-c | The FDA states MOTS-c is not a component of one (FDA briefing document, 11 May 2026) |
| ClinicalTrials.gov records for the term MOTS-c | 9, checked 14 October 2026 |
What is MOTS-c studied for in research?
MOTS-c is a lab research subject. Scientists use it to learn how mitochondria send signals to the rest of the cell. Lee and colleagues first described it in 2015. Since then, groups have tested it in cells grown in dishes and in rodents. They looked at blood sugar handling, fat build-up, muscle performance, inflammation and organ injury. Those are animal and cell results. The FDA states that MOTS-c is not part of any FDA-approved drug. USADA, the US anti-doping agency, calls it an experimental peptide being explored for use as a treatment. Every finding below reports what one study found.
MOTS-c studies come in three kinds. Cell experiments ask where MOTS-c goes inside a cell and which genes respond, as in a 2018 paper by Kim and colleagues. Mouse experiments ask what happens to blood sugar, body make-up and running ability, as in the papers by Lee in 2015 and Reynolds in 2021. Human studies mostly measure the body's own MOTS-c in blood, for example after exercise, as von Walden and colleagues did in 2021. Keeping these three kinds apart is the key to reading any headline about MOTS-c.
The same short molecule appears in several places on this site. The MOTS-c research guide walks through the first papers in plain English. MOTS-c in Perth covers where its code sits and how it is classified. This page asks a different question: what did the studies find?

Evidence limits
What has research not shown about MOTS-c?
The sources reviewed for this page do not show what MOTS-c does in people. FDA reviewers prepared a briefing for an advisory committee meeting in July 2026. They searched four large research databases: PubMed, Embase, the Cochrane Library and ClinicalTrials.gov. They found no clinical studies and no data on people exposed to MOTS-c. They wrote that the lab work was limited to cells and rodents. They also wrote that studies of how the amount tested relates to the effect were missing. A 2023 review by Zheng and colleagues says no working way to use MOTS-c in the clinic has been developed.
Even the amount of MOTS-c in blood is hard to pin down. A sports-testing laboratory studied a reference group of 20 healthy people. An antibody test called ELISA reported plasma MOTS-c of 45.9 to 218.5 ng/mL. Plasma is the liquid part of blood. A second method, mass spectrometry, could not confirm those values. This was a two-method comparison from one laboratory, published by Knoop and colleagues in 2019. So studies that compare blood levels between groups depend on which test each one used.
Mouse results do not carry over evenly either. In a 2021 study by Zempo and colleagues, male mice on a high-fat diet that received MOTS-c showed lower weight and improved glucose tolerance. Glucose tolerance is how well the body clears sugar from the blood. Female mice were unaffected. This mouse result does not show effects in people.
Research reference material is a separate matter from the molecules in these papers. The site catalogue lists MOTS-C reference material for laboratory work, and how to read a certificate of analysis explains what that paperwork can and cannot show about a batch.
What is MOTS-c best for?
The studies reviewed here cannot name a best use for MOTS-c. They asked different questions in different settings. Lee studied fat gain in mice. Reynolds tested mouse movement and natural MOTS-c around human exercise. Yoon measured natural blood levels in adults. None of those designs compares human treatments to find a best use.
Think of each study as a separate card. Lee's mouse card asks about fat gain and blood sugar. Reynolds' mouse card asks about running and movement. The human cards measure what the body already makes. Moving a finding from one card to another changes its meaning.
The MOTS-c trial record adds a study plan, rather than a result. NCT07505745 listed no results when checked 17 October 2026. A planned test cannot fill a results box.
What have studies of MOTS-c found?
Studies report results in three settings: cells, mice and people. In cells grown in dishes, MOTS-c switched on AMPK, an enzyme that senses energy. When sugar was scarce, it moved into the nucleus, the cell's control centre. In mice, MOTS-c prevented the obesity and insulin resistance caused by diet. Insulin resistance means the body responds poorly to insulin, the hormone that moves sugar into cells. In young, middle-aged and old mice, MOTS-c raised physical performance. None of these cell or mouse results shows the same effect in people. In people, studies measured only the body's own MOTS-c. No finished study giving MOTS-c to people for these outcomes was found.
The table below lines up eight studies by setting, so each result sits next to the model it came from. The last column says what each design cannot show.
The clearest human result is about the body's own MOTS-c. In 10 young men who did not usually exercise, exercise raised their natural MOTS-c about 11.9-fold in muscle and about 1.6-fold in blood. Reynolds and colleagues reported this in 2021. It was a small study, and nobody was given MOTS-c. No report of lab-made MOTS-c doing the same in a person was found in the sources searched.
In cells short of sugar, MOTS-c moved into the nucleus and changed the activity of stress-response genes. Some of these genes are controlled by proteins such as NRF2, a master switch for the cell's antioxidant defences. Kim and colleagues reported this in 2018 as a cell result, with no animal or human outcome. In test-tube work without cells, and in mouse muscle, MOTS-c bound to and switched on an enzyme called CK2. Kumagai and colleagues reported this in 2024 as a possible mechanism in lab and mouse models. It does not show the same action in people.
What does research show MOTS-c does in the body?
Lab studies suggest three ways MOTS-c may act, all in cells or mice. First, Lee and colleagues found in 2015 that MOTS-c blocks the folate pathway, a chain of chemical steps in the cell, and the purine production tied to it. Purines are building blocks of DNA. This leads to AMPK switching on. In mice, skeletal muscle seemed to be its main target organ. Second, Kim and colleagues found in 2018 that MOTS-c moves into the nucleus when sugar is short and controls stress-response genes. Third, Kumagai and colleagues found in 2024 that it binds the enzyme CK2. None of these results shows the same action in people.
Two cautions apply. First, FDA reviewers wrote in 2026 that the exact molecule MOTS-c acts on is still unknown. So the CK2 result is one proposed mechanism, not a settled one. Second, the effects differ by tissue. In the same mice, MOTS-c raised CK2 activity in muscle and lowered it in fat. This tissue-specific mouse finding does not show effects in people.
What have MOTS-c studies measured about muscle size and performance?
MOTS-c studies measured muscle size, physical performance and natural MOTS-c levels as separate things. The papers cited here do not show muscle growth in people given MOTS-c. In mice, Reynolds and colleagues measured treadmill running, balance on a rotating rod, grip strength and lean mass. Lean mass means all body tissue that is not fat, so it is not a direct measure of muscle growth alone. Kumagai and colleagues measured muscle in mice that could not move their hind legs. They also compared muscle mass across groups of people with different genes. These designs answer different questions. A running result cannot stand in for a muscle-size result.
Mouse performance results also depend on the test and the age group. Reynolds and colleagues found no change in grip strength in the young mice tested, even though running and rotating-rod results differed. The same paper measured MOTS-c in human muscle samples and blood around exercise. That human part tracked endogenous MOTS-c, meaning the MOTS-c the body makes itself. It did not test supplied MOTS-c or measure muscle growth from it. What MOTS-c is explains why a natural signal and a supplied molecule need separate evidence.
Kumagai and colleagues weighed the calf muscles of mice whose hind legs were held still. This is a model of atrophy, meaning muscle shrinkage. A separate human analysis used scans to estimate limb muscle mass in people with different versions of the MOTS-c genetic code. It found a link with low muscle mass. It did not test a treatment. Neither the held-still model nor the genetic comparison shows muscle gain in healthy people given MOTS-c. What tissue was measured, in which setting and against which group matters as much as the headline.
Does MOTS-c burn belly fat?
The papers reviewed here do not show that supplied MOTS-c reduces belly fat in people. The human blood study asked a different question. Yoon and colleagues measured MOTS-c that the body already makes. Levels were higher in adults with obesity. They stayed much the same after weight-loss surgery. Nobody received MOTS-c in that study.
In Yoon's study, blood levels were compared in 32 adults with obesity and 22 lean adults. Yoon's team also followed ten people for six months after weight-loss surgery. Their weight fell, but their blood MOTS-c did not show a clear change. The paper appeared online in December 2025, in the journal's 2026 volume.
Lee's 2015 paper reported less diet-related fat gain in mice given MOTS-c. That is a mouse treatment result. Yoon's human study measured natural blood levels. Neither record shows that giving MOTS-c to a person reduces belly fat. Blood levels and fat loss are separate measures.

Have studies of MOTS-c found changes in fat or body weight?
No study showing fat loss in people was found in the sources searched on 14 October 2026. In mice on a high-fat diet, Lee and colleagues found that treated mice did not become obese, even though they ate the same calories as untreated mice. In young mice, Reynolds and colleagues found less fat gain, with lean mass kept or raised. Old treated mice had lower fat mass. These mouse results do not show weight or appetite effects in people. In people, the registered Phase 2a trial NCT07505745 plans 120 participants. Its main outcome is insulin sensitivity, not weight.
In a separate study of cold, mice received MOTS-c after cold exposure. Brown fat is a type of fat that burns fuel to make heat. In those mice, heat-making genes in brown fat became more active. White fat became more like brown fat, which is called browning. Less fat travelled to the liver. Lu and colleagues reported this in 2019. It is an animal result and does not show the same changes in people.
Appetite results were mixed in mice. Lee and colleagues saw small drops in food intake in mice on a normal diet after 4 days. Yet mice on a high-fat diet ate the same calories as untreated mice. In old treated mice, Reynolds and colleagues found that total food intake fell, while body weight over their lifetime stayed similar. These are mouse results only. They do not show appetite or weight effects in people.
In people, studies describe the body's own MOTS-c, not MOTS-c given as a treatment. A 2026 study by Yoon and colleagues looked at 22 lean and 32 obese adults. Blood MOTS-c was higher in obesity, 273 versus 223 pg/mL. It did not change in 10 patients six months after weight-loss surgery. This is a link seen in a small, early-stage group. A meta-analysis combines the results of several studies. A 2024 meta-analysis by Zhou and colleagues pooled seven studies with 602 participants: six case-control studies and one cross-sectional study. It found lower blood MOTS-c in type 2 diabetes and higher levels in obesity. These are observational data from studies of different groups of people.
The only human trial result that touches weight belongs to CB4211. CB4211 is a modified MOTS-c analog, a related molecule with changes to its structure. So its results are not results for MOTS-c. In the 4-week Phase 1b stage, 20 adults with fatty liver disease took part: 11 on CB4211 and 9 on placebo. The company reported a trend toward lower body weight. Liver fat fell by similar amounts on CB4211 and on placebo, 5.03% and 4.88% in the company's table. These are headline figures from the CohBar annual report filed 29 March 2022, a company filing and not a peer-reviewed paper.
Can MOTS-c slow aging?
Reynolds and colleagues found better movement in old mice given MOTS-c. That does not show slower aging in people. The human part of the same paper measured natural MOTS-c around exercise. It did not test aging or give anyone the peptide. A mouse movement test and a human aging trial answer different questions.
In Reynolds' 2021 paper, old treated mice did better on grip, stride and walking tests. These tests measure physical ability near the end of life. They do not directly measure how fast every part of the body ages.
The same paper followed ten young men around exercise and a four-hour rest. That human work measured the body's own MOTS-c. It cannot show whether supplied MOTS-c changes human aging. Better movement in old mice also cannot establish a longer life in people.
Does MOTS-c increase testosterone?
A rat study reported higher testosterone after MOTS-c reached fluid spaces inside the brain. Testosterone is a hormone involved in sex traits and reproduction. This was a specialised brain experiment in male rats. It was not a human treatment trial. The human weight and exercise papers reviewed here do not establish this effect in people.
Öztürk and colleagues reported the rat findings in 2024. They also measured other hormone signals linked to reproduction. The brain setting matters: it differs from studying a substance moving through the blood. The result does not show a testosterone effect from MOTS-c in people.
A separate human paper by Filibeli and colleagues studied teenagers with polycystic ovary syndrome. This is a condition that affects hormone balance. That 2026 paper measured natural MOTS-c in blood. It did not test supplied MOTS-c. Measuring a natural peptide alongside a hormone condition does not show that adding it changes testosterone.
Has MOTS-c been studied in skin?
No study of MOTS-c on human skin was found on 14 October 2026. Neither registered trial that gives MOTS-c or an analog to people lists a skin outcome. A PubMed search for MOTS-c and the word skin, in titles and summaries, found two records that day. One study gave mice D-galactose, a sugar used to mimic ageing. In those mice, MOTS-c eased abnormal fat deposits in the liver, the fat around the organs and the dermis, the deeper layer of skin. That single mouse model is an early lead, not evidence about human skin. The other record, screened the same day, was a mouse study that did not measure skin.
In one cell study, scientists pushed human fibroblasts into senescence. Fibroblasts are connective-tissue cells. Senescence is a state in which cells stop dividing and release inflammatory signals. MOTS-c slightly raised how much the cells' mitochondria used oxygen, and raised some of the signals the cells release. Kim and colleagues reported this in 2018. This cell result does not show skin effects in people.
Two nearby findings are easy to mistake for human skin results. A 2026 animal study by Shi and colleagues looked at ischaemic surgical flaps: tissue moved from one body site to another that is short of blood supply. After MOTS-c treatment, blood flow and flap survival improved. The summary does not name the species. This animal result does not show skin-ageing effects in people. In a 2019 study by Che and colleagues, MOTS-c raised type I collagen gene and protein levels in a human bone-forming cell line. That test used no skin cells. It does not show skin effects in people.
Skin does appear in the record of CB4211, a different molecule. The sponsor's annual report for fiscal year 2022, filed 9 March 2023, says the Phase 1a/1b trial of CB4211 was suspended in November 2018. The pause was to deal with reactions at the site where the drug was given. This is a company statement about an analog. It gives no participant count for the Phase 1a stage in healthy people. It is not a peer-reviewed result, and it does not show that MOTS-c is safe.
Have studies reported sleepiness with MOTS-c?
No. The studies, trial records and regulator documents reviewed here did not report sleepiness from MOTS-c. The FDA searched its side-effect reporting system, called FAERS, for MOTS-c up to 9 March 2025. It found no reports. That is a search of reports, not a safety trial. The FDA also found no clinical studies or data on people exposed to MOTS-c. Australia's TGA lists insomnia and extreme tiredness among problems reported for unapproved peptide products as a group. It does not name MOTS-c. Studies that link MOTS-c to sleep measure the body's own level in people with sleep disorders. That says nothing about an effect of the peptide.
Where sleep appears in MOTS-c research, it appears as a disease marker. Obstructive sleep apnea is a condition in which breathing keeps stopping during sleep. In a 2025 study of 53 people with it and 24 controls, MOTS-c in serum, the clear liquid part of blood, was lower in people with more severe apnea. That is a link in a small study of the body's own peptide. In a 2021 study of 70 patients and 20 healthy controls, serum MOTS-c was lower with worse apnea. The more breathing pauses per hour of sleep a person had, the lower their MOTS-c (r = -0.492; r measures how closely two numbers move together). This observational link did not test supplied MOTS-c.
A 2019 study looked at blood immune cells from 10 people with chronic fatigue syndrome and 10 with Q fever fatigue syndrome. The gene that codes for MOTS-c was less active than in 10 healthy controls. This is a link in a small sample. It does not show that MOTS-c changes tiredness in either direction.
USADA's page, read 14 October 2026, reports many side effects among people who say they bought MOTS-c online. These include a faster heart rate or palpitations, irritation at the site of use, insomnia, local or whole-body immune reactions and fever. The page gives no count and no study design. So these are not trial results or a measured rate.
Have studies reported anxiety with MOTS-c?
No study found in the sources searched reports that MOTS-c causes anxiety. One 2026 study used a rat model of autism. Rats exposed to a drug called valproic acid became less social, repeated behaviours and showed anxiety. MOTS-c reversed all of these except the anxiety and the damage to the neocortex, the brain's outer layer. This is a rat result with no human data behind it. A PubMed search for MOTS-c with anxiety words found only that record on 14 October 2026. No human study has measured anxiety after MOTS-c. The Phase 2a trial record lists adverse events but no anxiety scale.
It is not even clear that MOTS-c reaches the brain. The blood-brain barrier is a tight wall of cells that controls what passes from the blood into the brain. In a 2021 mouse study, the authors reported that MOTS-c did not cross it. So they built a modified version that can pass into cells to carry it in. This mouse result does not show whether MOTS-c enters the human brain.
The registered Phase 2a trial plans 120 participants. One main outcome is treatment-emergent adverse events through 16 weeks, meaning unwanted health events that start during treatment. Its registry record, checked 14 October 2026, names no mood or sleep measure, and no results are posted.
Are there human clinical trials of MOTS-c?
One trial gives MOTS-c itself to people. On 14 October 2026, ClinicalTrials.gov listed it as NCT07505745. It is a Phase 2a study with a company sponsor. It has been recruiting in Shenzhen, China since 2 February 2026, and plans 120 participants. Its main outcomes are the change in insulin sensitivity at 12 weeks and unwanted health events through 16 weeks. Insulin sensitivity is how strongly the body responds to insulin. No results are posted. A search for the term MOTS-c found nine records in total. The other eight do not list MOTS-c as a treatment.
The PubMed trials that mention MOTS-c measure the body's own peptide. In one, 30 volunteers were randomly placed into endurance exercise, resistance exercise or no exercise. Blood MOTS-c showed a trend toward higher levels after endurance exercise. Another peptide, humanin, rose significantly, meaning the change was unlikely to be chance. This small trial did not test supplied MOTS-c. A second analysis used a 16-week exercise trial in 49 breast cancer survivors: 24 non-Hispanic White and 25 Hispanic. MOTS-c rose in the non-Hispanic White group, and the rise tracked with less fat mass. This small study measured the natural peptide and did not test supplied MOTS-c.
CB4211 is the nearest thing to a finished human trial. Its sponsor called CB4211 a new and improved analog of MOTS-c. Its Phase 1a/1b study ran from 9 July 2018 to 19 April 2021 with 88 participants, healthy adults and adults with fatty liver disease. The company reported no serious adverse events. In the 4-week Phase 1b stage, 11 adults with fatty liver disease took CB4211 and 9 took placebo. The company reported that the liver enzyme ALT fell 21% on CB4211, against a 4% rise on placebo. Another liver enzyme, AST, fell 28% against 11%. These are company figures for a different molecule, and the registry posts no results. The half-life page covers what the registry lists for it.
Which reviews describe the clinical status of MOTS-c?
Reviews from 2023 to 2026 describe MOTS-c as a research molecule with no established clinical use. A 2023 review by Zheng and colleagues says MOTS-c has been used less often to treat disease. It adds that no working way to use it in the clinic has been developed. A 2026 review by Mendias and Awan covered 12 peptides on the market, MOTS-c among them. It says careful human safety data for unapproved peptides are scarce. A 2026 review of inflammatory lung disease calls for well-designed studies in patients, run across many centres. It says these are needed to show whether changing or adding MOTS-c can affect the disease. That review tested nothing itself.
These reviews describe human evidence as limited. The studies on this page cannot settle how far a mouse result carries over to people. For the rules side of that gap, the MOTS-c legal status page sets out what the TGA, FDA and WADA have published.
Comparison
Eight studies sorted by setting. 'Result' is what the authors reported. 'Limit' is what the design cannot show. Checked against PubMed, ClinicalTrials.gov and the CB4211 sponsor's annual report on 14 October 2026. This is not a ranking and not a recommendation.
| Study | Setting | Result | Limit |
|---|---|---|---|
| Lee et al., Cell Metabolism, 2015 | Cells grown in dishes, and mice | AMPK switched on in cells; treated mice resisted the obesity and insulin resistance caused by diet | Cell and mouse evidence; does not establish a target organ or clinical effect in people |
| Kim et al., Cell Metabolism, 2018 | Cell lines short of sugar | MOTS-c moved to the nucleus and controlled stress-response genes | Cells only; no animal or human outcome |
| Reynolds et al., Nature Communications, 2021 | 10 young men who did not usually exercise; young, middle-aged and old mice | In the men, exercise raised the body's own MOTS-c, and nobody was given any. Treated mice did better on a treadmill, which does not show a performance effect in people | The human part measured the body's own MOTS-c; none was given to people |
| Li et al., Biochemical and Biophysical Research Communications, 2019 | Mice given D-galactose | MOTS-c eased fat build-up in three tissues, the dermis (deeper skin layer) among them | One mouse model; not tested in people |
| Kumagai et al., iScience, 2024 | Test-tube work, mice and Japanese groups of people with different genes | MOTS-c bound CK2 in test tubes and mice, which does not show the same action in people. In groups of 1,241 people for muscle mass, and 4,966 men and 6,890 women for type 2 diabetes, carriers of the K14Q gene version more often had low muscle mass. Men in their 60s who carried it more often had type 2 diabetes, but women in their 50s less often. These links did not test supplied MOTS-c | Gene-version results are links, not tests, and differed by sex |
| CB4211 Phase 1b, 2021 | 20 adults with fatty liver disease, 4 weeks | With 11 on the analog CB4211 and 9 on placebo, the liver enzymes ALT and AST fell more than on placebo, and liver fat fell by similar amounts in both groups. From the CohBar annual report of 29 March 2022, not a peer-reviewed paper | A MOTS-c analog, not MOTS-c; company report; 11 against 9 people |
| Yoon et al., Journal of Clinical & Translational Endocrinology, 2026 | 54 adults (22 lean, 32 obese) | Blood MOTS-c was higher in the 32 obese adults than in the 22 lean adults, and did not change in the 10 people who had weight-loss surgery | Measures the body's own peptide; a link in a small early-stage study |
| Zhou et al., Diabetology & Metabolic Syndrome, 2024 | Meta-analysis of seven studies, 602 participants | Blood MOTS-c was lower in type 2 diabetes and higher in obesity | Observational case-control and cross-sectional data from different groups of people; a link only |
FAQ
Does MOTS-c research establish muscle growth in people?
No. These papers do not show muscle growth in people given MOTS-c. In 2021, Reynolds and colleagues measured natural MOTS-c levels around exercise in people. In 2024, Kumagai and colleagues compared muscle mass across groups of people with different genes. Neither study tested whether supplied MOTS-c builds human muscle.
Is running farther the same as having larger muscles?
No. Running distance measures performance. Muscle mass measures the size of the tissue. Reynolds and colleagues measured running and body make-up separately in mice. A difference in running distance does not, by itself, show larger muscles, a stronger grip or a matching result in people.
What have studies found about MOTS-c and fat?
In mice on a high-fat diet, MOTS-c treatment limited fat gain. Old treated mice carried less fat. Neither result shows the same effect in people. No study showing fat loss in people from MOTS-c was found in the sources searched.
Have studies reported sleepiness with MOTS-c?
No study or regulator report found in the sources searched describes sleepiness with MOTS-c. The FDA searched its database of side-effect reports up to 9 March 2025 and found no MOTS-c reports. That reflects what people reported, not a safety trial.
Have studies reported anxiety with MOTS-c?
No study found in the sources searched links MOTS-c to anxiety as an effect. In one 2026 rat model, MOTS-c reversed several autism-like behaviours but not anxiety. That is a rat result with no human data behind it.
Has MOTS-c been studied in skin?
No human skin study was found in the PubMed search of 14 October 2026. In mice given D-galactose, MOTS-c eased fat deposits in the deeper skin layer. In human fibroblasts grown in dishes, MOTS-c slightly raised how much the cells' mitochondria used oxygen. Neither result shows skin effects in people.
What does MOTS-c stand for?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. An open reading frame is a stretch of genetic code that can spell out a peptide. This one sits inside a gene in the mitochondria.
Does exercise raise MOTS-c in people?
In 10 healthy young men who did not usually exercise, natural MOTS-c rose about 11.9-fold in muscle after cycling and about 1.6-fold in blood during cycling. That small study did not give anyone MOTS-c. In another study, 30 volunteers were randomly placed into endurance exercise, resistance exercise or no exercise. Blood MOTS-c showed only a trend toward higher levels after endurance exercise. That small trial also measured only the natural peptide.
Is MOTS-c the same as CB4211?
No. CB4211 is an analog: a related molecule with changes to its structure. Its developer called it an improved analog of MOTS-c in its annual report of 29 March 2022. CB4211 results do not carry over to MOTS-c.
Has the Phase 2a trial of MOTS-c reported results?
No results are posted. The registry record, checked 14 October 2026, was last updated on 1 April 2026. It gives an estimated primary completion date of 14 February 2027.
More in this hub
Citations
25 sourcesLee C, Zeng J, Drew BG, et al. Cell Metabolism. 2015;21(3):443-454.
doi:10.1016/j.cmet.2015.02.009Kim KH, Son JM, Benayoun BA, Lee C Cell Metabolism. 2018;28(3):516-524.e7.
doi:10.1016/j.cmet.2018.06.008Reynolds JC, Lai RW, Woodhead JST, et al. Nature Communications. 2021;12:470.
doi:10.1038/s41467-020-20790-0von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Journal of Applied Physiology. 2021;131(3):1035-1042.
doi:10.1152/japplphysiol.00706.2019Kumagai H, Kim SJ, Miller B, et al. iScience. 2024;27(11):111212.
doi:10.1016/j.isci.2024.111212Zempo H, Kim SJ, Fuku N, et al. Aging. 2021;13(2):1692-1717.
doi:10.18632/aging.202529Lu H, Tang S, Xue C, et al. International Journal of Molecular Sciences. 2019;20(10):2456.
doi:10.3390/ijms20102456Li Q, Lu H, Hu G, et al. Biochemical and Biophysical Research Communications. 2019;513(2):439-445.
doi:10.1016/j.bbrc.2019.03.194Kim SJ, Mehta HH, Wan J, et al. Aging. 2018;10(6):1239-1256.
doi:10.18632/aging.101463Shi J, Wu Y, Liu X, et al. Autophagy. 2026;22(10):2695-2724.
doi:10.1080/15548627.2026.2677180Che N, Qiu W, Wang JK, et al. European Review for Medical and Pharmacological Sciences. 2019;23(8):3183-3189.
doi:10.26355/eurrev_201904_17676Yoon SH, Yuan F, Zhu X, et al. Journal of Clinical & Translational Endocrinology. 2026;43:100429.
doi:10.1016/j.jcte.2025.100429Zhou Q, Yin S, Lei X, et al. Diabetology & Metabolic Syndrome. 2024;16(1):200.
doi:10.1186/s13098-024-01405-wDieli-Conwright CM, Sami N, Norris MK, et al. Scientific Reports. 2021;11(1):16916.
doi:10.1038/s41598-021-96419-zLuo Z, Ji R, Ye R, et al. Sleep and Biological Rhythms. 2025;23(3):305-311.
doi:10.1007/s41105-025-00578-9Baylan FA, Yarar E Sleep and Breathing. 2021;25(2):861-866.
doi:10.1007/s11325-020-02273-0Raijmakers RPH, Jansen AFM, Keijmel SP, et al. Journal of Translational Medicine. 2019;17(1):157.
doi:10.1186/s12967-019-1906-3Güvenir Seven S, Sahin H, Erkanlı Şentürk G, et al. Molecular Neurobiology. 2026;63(1):453.
doi:10.1007/s12035-026-05741-yJiang J, Chang X, Nie Y, et al. ACS Chemical Neuroscience. 2021;12(9):1506-1518.
doi:10.1021/acschemneuro.0c00782Knoop A, Thomas A, Thevis M Rapid Communications in Mass Spectrometry. 2019;33(4):371-380.
doi:10.1002/rcm.8337Zheng Y, Wei Z, Wang T Frontiers in Endocrinology. 2023;14:1120533.
doi:10.3389/fendo.2023.1120533Mendias CL, Awan TM Sports Medicine. 2026;56(8):1921-1935.
doi:10.1007/s40279-026-02437-0Amado CA, Agüero J, García-Unzueta M, et al. Journal of Translational Medicine. 2026;24(1).
doi:10.1186/s12967-026-08398-2Öztürk DAO, Erden Y, Tekin S Neuroscience Letters. 2024;826:137722.
doi:10.1016/j.neulet.2024.137722Filibeli BE, Dedemoglu F, Garipçin P, et al. Archives of Endocrinology and Metabolism. 2026;70(3):e260031.
doi:10.20945/2359-4292-2026-0031
Continue
MOTS-C reference materialResearch use only: not for human or animal use.
Read the MOTS-c research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
